The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2017 | Bendamustine plus rituximab vs. standard therapy for advanced CLL
Fludarabine, cyclophosphamide and rituximab (FCR) is the standard chemotherapy regimen used to treat chronic lymphocytic leukaemia (CLL). In this interview, Barbara Eichhorst, MD, of the University Hospital Cologne, Cologne, Germany, provides an overview of the Phase III CLL10 study (NCT00769522), which compared the efficacy and tolerance of FCR vs. bendamustine in combination with rituximab. This interview was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
